DOD Awards Dynavax $22 Million for Plague Vaccine Clinical Trial

The U.S. Department of Defense (DOD) awarded Dynavax Technologies Corporation with an agreement worth approximately $22 million over two and a half years, to execute a clinical trial combining the DOD’s recombinant plague (rF1V) vaccine with its own CpG 1018® adjuvant. Under the agreement,

...

Continue Reading

FDA approves first treatment for Ebola

On October 14 the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric

...

Continue Reading

CEPI grants $9M to Inovio to develop coronavirus vaccine

Inovio Pharmaceuticals, USA has announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's

...

Continue Reading

Cyanide Autoinjector Development

The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning.

Under the grant, researchers from the

...

Continue Reading

Our Current Sponsors